<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998308</url>
  </required_header>
  <id_info>
    <org_study_id>October6U-0001</org_study_id>
    <nct_id>NCT01998308</nct_id>
  </id_info>
  <brief_title>Comparison Between Four Types of Single Dose Hyaluronic Acid Injection in Patients With Knee Osteoarthritis</brief_title>
  <official_title>Intra-articular Hyaluronic Acid Knee Injection: Randomized Control Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>October 6 University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>October 6 University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design:

      Allocation: Randomized. Endpoint Classification: Comparative Study. Intervention model:
      Parallel Assignment. Masking: Double Blind (Subject, Assessed) Primary purpose: Comparison.

      Official Title: Intra-articular hyaluronic acid knee injection: randomized control trail.

      Primary outcome measures:

        -  Lower extremity functional scale

        -  Visual analogue scale

        -  Range of motion

        -  Kellgren and Lawrence class grade Estimated enrollment: 100 Study start date: December
           2012 Estimated study completion date: June 2013 Estimated primary completion date:
           December 2013
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study include:

      200 knees, 50 knees will have single injection of Crespine gel, and 50 knees will have single
      injection of 2 ampules of Intragel, also 50 knees will have single injection of Crespine plus
      gel and 50 knees will have single injection of Monovisc The patient will be randomized to
      Crespine gel or to Intragel, and Crespine Plus gel or to Monovisc

      Inclusion Criteria: patients with Osteoarthritis grade II and III according to Kellgren and
      Lawrence grading were included.

      Exclusion Criteria: patients with autoimmune illnesses, active inflammation or infected
      processes, anticoagulant, and known allergy to hyaluronic acid.

      Target parameters:

        -  Lower extremity functional scale

        -  Visual analogue scale

        -  Range of motion

        -  Kellgren and Lawrence class grade

      Eligibility:

      Ages Eligible for Study: 20 years to 70 years Genders Eligible for Study: both Accepts
      Healthy Volunteers: no

      Criteria

      Inclusion Criteria:

        -  Age of patients between 20 and 70 years

        -  patients with Osteoarthritis grade II and III according to Kellgren and Lawrence grading

      Exclusion Criteria:

        -  Autoimmune illnesses

        -  Active inflammation or infected processes

        -  Anticoagulant

        -  Known allergy to hyaluronic acid.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Lower extremity functional scale</measure>
    <time_frame>up to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kellgren and lawrence class grade</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of motion</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>50 Knees will have single injection of Crespine gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>50 Knees will have single injection of 2 ampules of intragel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>50 knees will have single injection of crespine plus gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>50 knees will have single injection of Monovisc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crespine gel</intervention_name>
    <description>50 Knees will have single injection of Crespine gel</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intragel</intervention_name>
    <description>50 Knees will have single injection of 2 ampules of Intragel</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crespine plus gel</intervention_name>
    <description>50 Knees will have single injection of Crespine Plus Gel</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monovisc</intervention_name>
    <description>50 Knees will have single injection of Monovisc</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient with knee osteoarthiritis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of patients between 20 and 70 years

          -  patients with Osteoarthritis grade II and III according to Kellgren and Lawrence
             grading

        Exclusion Criteria:

          -  Autoimmune illnesses

          -  Active inflammation or infected processes

          -  Anticoagulant

          -  Known allergy to hyaluronic acid.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud A Hafez, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>October 6 University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdullah I Ammoura, Researcher</last_name>
    <role>Study Chair</role>
    <affiliation>Bone and Joint Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud A Hafez, Professor</last_name>
    <phone>002 0100 1116624</phone>
    <email>mhafez@msn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdullah I Ammoura, Researcher</last_name>
    <phone>00201118581127</phone>
    <email>abdala.ammora@mhafez.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>October 6 University</name>
      <address>
        <city>six October city</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud A Hafez, Professor</last_name>
      <phone>00201001116624</phone>
      <email>mhafez@msn.com</email>
    </contact>
    <contact_backup>
      <last_name>Abdullah I Ammoura, Researcher</last_name>
      <phone>00201118581127</phone>
      <email>mixecano1991@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mahmoud A Hafez, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2013</study_first_submitted>
  <study_first_submitted_qc>November 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>October 6 University</investigator_affiliation>
    <investigator_full_name>Mahmoud A Hafez, MSc Orth, Dip SICOT, FRCS Ed, MD</investigator_full_name>
    <investigator_title>Mahmoud A Hafez</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

